My talk at the Open PHACTS last ever project meeting in Vienna 2016 where i was asked to talk about the challenges we addressed in open phacts with semantic web technology and what still needed to be done.
Edge Informatics and FAIR (Findable, Accessible, Interoperable and Reusable) ...Tom Plasterer
Edge Informatics is an approach to accelerate collaboration in the BioPharma pipeline. By combining technical and social solutions knowledge can be shared and leveraged across the multiple internal and external silos participating in the drug development process. This is accomplished by making data assets findable, accessible, interoperable and reusable (FAIR). Public consortia and internal efforts embracing FAIR data and Edge Informatics are highlighted, in both preclinical and clinical domains.
This talk was presented at the Molecular Medicine Tri-Conference in San Francisco, CA on February 20, 2017
A presentation to the New Year's Event for Maastricht University's Knowledge Engineering @ Work Program. https://www.maastrichtuniversity.nl/news/kework-first-10-students-academic-workstudy-track-graduate
Edge Informatics and FAIR (Findable, Accessible, Interoperable and Reusable) ...Tom Plasterer
Edge Informatics is an approach to accelerate collaboration in the BioPharma pipeline. By combining technical and social solutions knowledge can be shared and leveraged across the multiple internal and external silos participating in the drug development process. This is accomplished by making data assets findable, accessible, interoperable and reusable (FAIR). Public consortia and internal efforts embracing FAIR data and Edge Informatics are highlighted, in both preclinical and clinical domains.
This talk was presented at the Molecular Medicine Tri-Conference in San Francisco, CA on February 20, 2017
A presentation to the New Year's Event for Maastricht University's Knowledge Engineering @ Work Program. https://www.maastrichtuniversity.nl/news/kework-first-10-students-academic-workstudy-track-graduate
Building a Network of Interoperable and Independently Produced Linked and Ope...Michel Dumontier
Over 15 years ago, Sir Tim Berners Lee proclaimed the founding of an exciting new future involving intelligent agents operating over smarter data in order to perform complex tasks at the behest of their human controllers. At the heart of this vision lies an uneasy alliance between tedious formal knowledge representations and powerful analytics over big, but often messy data. Bio2RDF, our decade old open source project to create Linked Data for the life sciences, has weaved emergent Semantic Web technologies such as ontologies and Linked Data to generate FAIR - Findable, Accessible, Interoperable, and Reusable - data in the form of billions of machine accessible statements for use in downstream biomedical discovery.
This revolution in data publication has been strengthened by action from global bioinformatics institutions such as the NCBI, NCBO, EBI, and DBCLS. Notably, NCBI's PubChem has successfully coupled large scale data integration with community-based standards to offer a remakable biochemical knowledge resource amenable to data hungry discovery tools. Yet, in the face of increasing pressure from researchers, funders, and publishers, will these approaches be sufficient for growing and maintaining a comprehensive knowledge graph that is inclusive of all biomedical research?
ChemSpider was developed with the intention of aggregating and indexing available sources of chemical structures and their associated information into a single searchable repository and making it available to everybody, at no charge. There are many tens of chemical structure databases such as literature data, chemical vendor catalogs, molecular properties, environmental data, toxicity data, analytical data etc. and no single way to search across them. Despite the diversity of databases available online their inherent quality, accuracy and completeness is lacking in many regards. ChemSpider was established to provide a platform whereby the chemistry community could contribute to cleaning up the data, improving the quality of data online and expanding the information available to include data such as reaction syntheses, analytical data and experimental properties. ChemSpider has now grown into a database of over 20 million chemical substances integrated with over 300 disparate data sources, many of these directly supporting the Life Sciences. This presentation will provide an overview of our efforts to improve the quality of data online, to provide a foundation for the semantic web for chemistry and to provide access to a set online tools and services to support access to these data. I will also discuss how ChemSpider is being used to enhance Semantic Publishing in Chemistry at RSC.
Slides of the 2015 Bio Data World Congress show how our analyzegenomes.com services are combined to support precision medicine in the context of modern oncology treatment.
Bio2RDF is an open-source project that offers a large and
connected knowledge graph of Life Science Linked Data. Each dataset is expressed using its own vocabulary, thereby hindering integration, search, query, and browse data across similar or identical types of data. With growth and content changes in source data, a manual approach to maintain mappings has proven untenable. The aim of this work is to develop a (semi)automated procedure to generate high quality mappings
between Bio2RDF and SIO using BioPortal ontologies. Our preliminary results demonstrate that our approach is promising in that it can find new mappings using a transitive closure between ontology mappings. Further development of the methodology coupled with improvements in
the ontology will offer a better-integrated view of the Life Science Linked Data
Making it Easier, Possibly Even Pleasant, to Author Rich Experimental MetadataMichel Dumontier
Biomedical researchers will remain stymied in their ability to take full advantage of the Big Data revolution if they can never find the datasets that they need to analyze, if there is lack of clarity about what particular datasets contain, and if data are insufficiently described.
CEDAR, an NIH BD2K Center of Excellence, aims to develop methods and tools to vastly ease the burden of authoring good experimental metadata, and to maximally use this information to zero in on datasets of interest.
Research Data Sharing: A Basic FrameworkPaul Groth
Some thoughts on thinking about data sharing. Prepared for the 2016 LERU Doctoral Summer School - Data Stewardship for Scientific Discovery and Innovation.
http://www.dtls.nl/fair-data/fair-data-training/leru-summer-school/
Semantic web technologies offer a potential mechanism for the representation and integration of thousands of biomedical databases. Many of these databases offer cross-references to other data sources, but these are generally incomplete and prone to error. In this paper, we conduct an empirical analysis of the link structure of life science Linked Data, obtained from the Bio2RDF project. Three different link graphs for datasets, entities and terms are characterized by degree, connectivity, and clustering metrics, and their correlation is measured as well. Furthermore, we utilize the symmetry and transitivity of entity links to build a benchmark and evaluate several popular entity matching approaches. Our findings indicate that the life science data network can help find hidden links, can be used to validate links, and may offer a mechanism to integrate a wider set of resources to support biomedical knowledge discovery.
This presentation shares a 10 minute pitch of big data potentials in the field of life sciences as presented at the 2015 CMS Global Life Science Forum on Nov 9, 2015 in Frankfurt
Access to consistent, high-quality metadata is critical to finding, understanding, and reusing scientific data. This document describes a consensus among participating stakeholders in the Health Care and the Life Sciences domain on the description of datasets using the Resource Description Framework (RDF). This specification meets key functional requirements, reuses existing vocabularies to the extent that it is possible, and addresses elements of data description, versioning, provenance, discovery, exchange, query, and retrieval.
Usage of open source software for Real World Data Analysis in pharmaceutical ...Kees van Bochove
An upcoming area of interest for biopharmaceutical product development, as well as for public health and healthcare system evaluation, is the study of medical outcomes in so-called 'real world data'. This data can originate from electronic medical records in hospitals, general practitioners, pharmacies, insurance companies and even directly from patients, using forums or mobile health apps.
One of the largest open source initiatives for the standardisation and analysis for this type of data is called OHDSI: Observational Health Data Sciences and Informatics. OHDSI leverages the OMOP data model for observational data, and provides data analysis tools for a broad range of use cases. This talk will focus on a number of examples of the application of the OHDSI tooling for observational research, as well as provide a broader introduction of the topic and the use of open source software in pharmaceutical and healthcare context.
The presenter, Kees van Bochove, is founder and CEO of The Hyve, a company based in Utrecht, The Netherlands and Cambridge, MA, US that provides services around open source software in bioinformatics and translational research, such as OHDSI, tranSMART and cBioPortal.
Scientists commonly find themselves in a state of overwhelm in regards to the availability of information accessible to them. The distribution of resources now includes the entire space of the worldwide web, access to primary databases such as CAS and, commonly, a plethora of internally developed systems. While the web has provided improved access to chemistry-related information there has not been an online central resource allowing integrated chemical structure-searching of chemistry databases, chemistry articles, patents and web pages such as blogs and wikis. ChemSpider has built a structure centric community for chemists by providing free access to an online database and collaboration tool for chemists. The online database offers an environment for curating the data on ChemSpider as well as the deposition of chemical structures, analytical data and associated information and provides a significant knowledge base and resource for chemists working in different domains. An overview of present and future capabilities is given.
An invited talk for Lilly's Global IT Seminar Meeting In November 2016 on the subject of data, machine learning, AI, semantic web, text mining and spinach!
I recently was asked what sort of things i have considered in my experience of performing data integration in pharma for drug discovery. So here's the ten things i thought most important!
Building a Network of Interoperable and Independently Produced Linked and Ope...Michel Dumontier
Over 15 years ago, Sir Tim Berners Lee proclaimed the founding of an exciting new future involving intelligent agents operating over smarter data in order to perform complex tasks at the behest of their human controllers. At the heart of this vision lies an uneasy alliance between tedious formal knowledge representations and powerful analytics over big, but often messy data. Bio2RDF, our decade old open source project to create Linked Data for the life sciences, has weaved emergent Semantic Web technologies such as ontologies and Linked Data to generate FAIR - Findable, Accessible, Interoperable, and Reusable - data in the form of billions of machine accessible statements for use in downstream biomedical discovery.
This revolution in data publication has been strengthened by action from global bioinformatics institutions such as the NCBI, NCBO, EBI, and DBCLS. Notably, NCBI's PubChem has successfully coupled large scale data integration with community-based standards to offer a remakable biochemical knowledge resource amenable to data hungry discovery tools. Yet, in the face of increasing pressure from researchers, funders, and publishers, will these approaches be sufficient for growing and maintaining a comprehensive knowledge graph that is inclusive of all biomedical research?
ChemSpider was developed with the intention of aggregating and indexing available sources of chemical structures and their associated information into a single searchable repository and making it available to everybody, at no charge. There are many tens of chemical structure databases such as literature data, chemical vendor catalogs, molecular properties, environmental data, toxicity data, analytical data etc. and no single way to search across them. Despite the diversity of databases available online their inherent quality, accuracy and completeness is lacking in many regards. ChemSpider was established to provide a platform whereby the chemistry community could contribute to cleaning up the data, improving the quality of data online and expanding the information available to include data such as reaction syntheses, analytical data and experimental properties. ChemSpider has now grown into a database of over 20 million chemical substances integrated with over 300 disparate data sources, many of these directly supporting the Life Sciences. This presentation will provide an overview of our efforts to improve the quality of data online, to provide a foundation for the semantic web for chemistry and to provide access to a set online tools and services to support access to these data. I will also discuss how ChemSpider is being used to enhance Semantic Publishing in Chemistry at RSC.
Slides of the 2015 Bio Data World Congress show how our analyzegenomes.com services are combined to support precision medicine in the context of modern oncology treatment.
Bio2RDF is an open-source project that offers a large and
connected knowledge graph of Life Science Linked Data. Each dataset is expressed using its own vocabulary, thereby hindering integration, search, query, and browse data across similar or identical types of data. With growth and content changes in source data, a manual approach to maintain mappings has proven untenable. The aim of this work is to develop a (semi)automated procedure to generate high quality mappings
between Bio2RDF and SIO using BioPortal ontologies. Our preliminary results demonstrate that our approach is promising in that it can find new mappings using a transitive closure between ontology mappings. Further development of the methodology coupled with improvements in
the ontology will offer a better-integrated view of the Life Science Linked Data
Making it Easier, Possibly Even Pleasant, to Author Rich Experimental MetadataMichel Dumontier
Biomedical researchers will remain stymied in their ability to take full advantage of the Big Data revolution if they can never find the datasets that they need to analyze, if there is lack of clarity about what particular datasets contain, and if data are insufficiently described.
CEDAR, an NIH BD2K Center of Excellence, aims to develop methods and tools to vastly ease the burden of authoring good experimental metadata, and to maximally use this information to zero in on datasets of interest.
Research Data Sharing: A Basic FrameworkPaul Groth
Some thoughts on thinking about data sharing. Prepared for the 2016 LERU Doctoral Summer School - Data Stewardship for Scientific Discovery and Innovation.
http://www.dtls.nl/fair-data/fair-data-training/leru-summer-school/
Semantic web technologies offer a potential mechanism for the representation and integration of thousands of biomedical databases. Many of these databases offer cross-references to other data sources, but these are generally incomplete and prone to error. In this paper, we conduct an empirical analysis of the link structure of life science Linked Data, obtained from the Bio2RDF project. Three different link graphs for datasets, entities and terms are characterized by degree, connectivity, and clustering metrics, and their correlation is measured as well. Furthermore, we utilize the symmetry and transitivity of entity links to build a benchmark and evaluate several popular entity matching approaches. Our findings indicate that the life science data network can help find hidden links, can be used to validate links, and may offer a mechanism to integrate a wider set of resources to support biomedical knowledge discovery.
This presentation shares a 10 minute pitch of big data potentials in the field of life sciences as presented at the 2015 CMS Global Life Science Forum on Nov 9, 2015 in Frankfurt
Access to consistent, high-quality metadata is critical to finding, understanding, and reusing scientific data. This document describes a consensus among participating stakeholders in the Health Care and the Life Sciences domain on the description of datasets using the Resource Description Framework (RDF). This specification meets key functional requirements, reuses existing vocabularies to the extent that it is possible, and addresses elements of data description, versioning, provenance, discovery, exchange, query, and retrieval.
Usage of open source software for Real World Data Analysis in pharmaceutical ...Kees van Bochove
An upcoming area of interest for biopharmaceutical product development, as well as for public health and healthcare system evaluation, is the study of medical outcomes in so-called 'real world data'. This data can originate from electronic medical records in hospitals, general practitioners, pharmacies, insurance companies and even directly from patients, using forums or mobile health apps.
One of the largest open source initiatives for the standardisation and analysis for this type of data is called OHDSI: Observational Health Data Sciences and Informatics. OHDSI leverages the OMOP data model for observational data, and provides data analysis tools for a broad range of use cases. This talk will focus on a number of examples of the application of the OHDSI tooling for observational research, as well as provide a broader introduction of the topic and the use of open source software in pharmaceutical and healthcare context.
The presenter, Kees van Bochove, is founder and CEO of The Hyve, a company based in Utrecht, The Netherlands and Cambridge, MA, US that provides services around open source software in bioinformatics and translational research, such as OHDSI, tranSMART and cBioPortal.
Scientists commonly find themselves in a state of overwhelm in regards to the availability of information accessible to them. The distribution of resources now includes the entire space of the worldwide web, access to primary databases such as CAS and, commonly, a plethora of internally developed systems. While the web has provided improved access to chemistry-related information there has not been an online central resource allowing integrated chemical structure-searching of chemistry databases, chemistry articles, patents and web pages such as blogs and wikis. ChemSpider has built a structure centric community for chemists by providing free access to an online database and collaboration tool for chemists. The online database offers an environment for curating the data on ChemSpider as well as the deposition of chemical structures, analytical data and associated information and provides a significant knowledge base and resource for chemists working in different domains. An overview of present and future capabilities is given.
An invited talk for Lilly's Global IT Seminar Meeting In November 2016 on the subject of data, machine learning, AI, semantic web, text mining and spinach!
I recently was asked what sort of things i have considered in my experience of performing data integration in pharma for drug discovery. So here's the ten things i thought most important!
Pistoia Alliance SESL pilot Bio IT World Hanover 12 Oct 2011Ian Harrow
Towards a brokering framework for knowledge-based services: learning from the Pistoia Alliance SESL pilot
Ian Harrow PhD for the Pistoia Alliance
This presentation describes a pilot project to determine the feasibility of biomedical knowledge brokering. It shows query across multiple disparate data sources through a brokering demonstrator built from RDF triple store technology. The learning from this pilot is contributing to larger scale projects such as the Innovative Medicines Initiative, OpenPFACTs.
Building a Platform for the People - IBM's Open Cloud Architecture Summit - A...Chip Childers
A talk for the IBM Open Cloud Architecture Summit event in Atlanta in September 2015, discussing the "why" behind the Cloud Foundry platform and movement.
We know that agile methodologies work at the team level, and there is now even an effort to scale into whole organizations.
There is a clear reason behind this: we found ways to improve performance, by analyzing situations better, and making better decision. Every organization wants to apply this in every level. Like in the late 90s, new ideas are coming out that challenge the way we think, and this time they don't just answer development. Ideas like Beyond Budgeting, Lean Startup, Cynefin, Real Options, Feature Injection, SAFe, Design Thinking, #NoEstimates, Cost of Delay and others are spreading out, and while we know not all will last, you never know which might fit your situation. In this session, I'll give a summary of what's hot around the agile world, with some criticism and application in the real world. 13 years after the original manifesto, organizations start to experiment again. I always wished I was there when the first conversations took place. I encourage you to join in on current conversations. Let's start.
Esta presentación te ayudará a preparar tus archivos de la forma adecuada teniendo en cuenta el tipo de impresión que realices o el formato de archivo que se solicite.
Scott Edmunds slides for class 8 from the HKU Data Curation (module MLIM7350 from the Faculty of Education) course covering open science and data publishing
Doing more with less resources used to be a situation common just for academic scientists. This is unfortunately still true for academics but we are seeing others facing many of the same challenges. With the squeeze on budgets and cost cutting resulting from recent worldwide economic challenges, the failure of many drugs to make it through the pipeline to the market, and the increasing costs associated with the drug development process, we are now seeing in the pharmaceutical industry a dramatic shift, perhaps belatedly, to have to accommodate similar challenges of doing more with less
This is a presentation I gave at the Library of Congress as part of a NFAIS/FLICC/CENDI meeting as outlined here: http://www.chemspider.com/blog/making-the-web-work-for-science-presentation-at-the-library-of-congress.html
The presentation provides an overview of some of the challenges the publishers face moving forward, how they are responding to it, how InChI is an enabling technology, how quality is important.
ASIDIC Spring Meeting, Las Vegas, NV March 2008. This presentation presents the challenges for the researcher, publisher and the library as their collective worlds are constantly colliding as the need to be published, to maintain the subscription model
Scott Edmunds slides from class 7 from the HKU Data Curation (module MLIM7350 from the Faculty of Education) course covering open data policy and practice, and the Hong Kong context.
Open Source Collaboration in Drug Discovery in PharmaKees van Bochove
How pre-competitive collaboration in the pharmaceutical sector through open source platforms enables joint innovation of academics, pharma, SMEs and non-profits.
Open Research Practices in the Age of a Papermill PandemicDorothy Bishop
Talk given to Open Research Group, Maynooth University, October 2022.
Describes the phenomenon of large-scale fraudulent science publishing (papermills), and discusses how open science practices can help tackle this.
The Path to Open Science with Illustrations from Computational Biology - A presentation made at the Microsoft 2011 Latin America Faculty Summit Cartagena, Columbia, May 18, 2011.
With the recent announcement that GlaxoSmithKline have released a huge tranche of whole cell malaria screening data to the public domain, accompanied by a corresponding publication, this raises some issues for consideration before this exemplar instance becomes a trend. We have examined the data from a high level, by studying the molecular properties, and consider the various alerts presently in use by major pharma companies. We acknowledge the potential value of such data but also raise the issue of the actual value of such datasets released into the public domain. We also suggest approaches that could enhance the value of such datasets to the community and theoretically offer more immediate benefit to the search for leads for other neglected diseases.
The slides that will accompany my live webcast for OpenCon 2014 attendees, all about open data in research. The benefits, the how to (both legally & technically), examples, pitfalls, and the future of open research data.
TranSMART: How open source software revolutionizes drug discovery through cro...keesvb
Presentation about the use of open source software in pharmaceutical companies at Global Discovery & Development Innovation Summit (GDDIS) in Princeton, NY, fall 2013.
Scott Edmunds slides for class 8 from the HKU Data Curation (module MLIM7350 from the Faculty of Education) course covering science data, medical data and ethics, and the FAIR data principles.
Recomendations for infrastructure and incentives for open science, presented to the Research Data Alliance 6th Plenary. Presenter: William Gunn, Director of Scholarly Communications for Mendeley.
PubChem for chemical information literacy trainingSunghwan Kim
Presented at the American Chemical Society Fall 2021 National Meeting (August 23, 2021; virtual).
==== Abstracts ====
PubChem (https://pubchem.ncbi.nlm.nih.gov) is a public chemical information resource that collects chemical information from 780+ data sources. It is visited by millions of users every month and many of them are young students at academic undergraduate or graduate students at academic institutions. While PubChem has a great potential as an online resource for chemical education, it also has important issues that are not familiar to students and educators, including data accuracy, data provenance, structure standardization, terminologies, etc. In this presentation, various aspects of PubChem as a chemical education resource will be discussed, with a special emphasis on how to help students develop chemical information literacy skills.
Similar to Open PHACTS : Linked Data Future Challenges (20)
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
9. A second concern held by some is that a new class of research person will
emerge — people who had nothing to do with the design and execution of
the study but use another group’s data for their own ends, possibly stealing
from the research productivity planned by the data gatherers, or even use the
data to try to disprove what the original investigators had posited. There is
concern among some front-line researchers that the system will be taken over
by what some researchers have characterized as “research parasites”
Rather than labelling
people parasites, lets
make the tools to
ensure credit for all
involved!
10. …. Prior to this…
However, many of us who have actually conducted clinical
research, managed clinical studies and data collection and
analysis, and curated data sets have concerns about the
details. The first concern is that someone not involved in
the generation and collection of the data may not
understand the choices made in defining the parameters.
Special problems arise if data are to be combined from independent
studies and considered comparable. How heterogeneous were the
study populations? Were the eligibility criteria the same….
Actually a very fair
comment
12. ……estimates for the reproducibility of preclinical research range
from 51 percent to 89 percent. They estimate that at least half of
all U.S. preclinical biomedical research funding—about $28 billion
annually—is therefore squandered……
http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002165
But is this just an
“academic” problem,
or should industry
care?
16. http://www.nature.com/nrd/journal/v10/n9/full/nrd3439-c1.html
A first-of-a-kind analysis of Bayer's internal
efforts to validate 'new drug target' claims now
not only supports this view but suggests that
50% may be an underestimate; the company's
in-house experimental data do not match
literature claims in 65% of target-validation
projects, leading to project discontinuation.
Industry should
*really* care
22. Quality Of The Experiment
Independent Confirmations
Negative Assertions
Literature “dead ends”
Social Commentary / Sentiment Analysis
Marking Questionable Assertions
33. ORPHANET Rare/Orphan
disease
Dynamic Phenotype
Network In RDF
Generated by TERMite
PhenotypeFinder
Ack. Michael Hughes
http://scibite.com
SciBite
Yellow = disease, pink
= on-the-fly
phenotype concept
generated by text
mining (not found in
HPO)
69. Researchers have found that
removing a gene called USF1
protects mice against heart
disease, diabetes and obesity
We don’t yet have a
system where we can
just jump and explore
the biology and
chemistry of the USF1
pathways….